ArticleContemporary clinical trials communications2026

Orforglipron for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity or overweight: Study design and baseline characteristics of ATTAIN-OSA, a phase 3 trial.

Atul Malhotra et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.